Novel Anticancer Drug Candidate from Frontier Medicines
Receives IND Approval for Phase 1/2 Clinical Trials

LG Chem announced on June 30 that it has received approval from the U.S. Food and Drug Administration (FDA) for the Investigational New Drug (IND) application for its anticancer drug candidate, LG00313112, for phase 1 and 2 clinical trials.


LG Chem Corporate Logo Image. LG Chem

LG Chem Corporate Logo Image. LG Chem

View original image

LG00313112 is a novel drug candidate that LG Chem acquired from U.S.-based Frontier Medicines in April. LG Chem has secured exclusive global rights for development and commercialization, excluding Greater China.


This compound targets the 'TP53 Y220C' mutation, which occurs in 1–3% of all cancer patients. TP53 is a well-known tumor suppressor gene that helps prevent cancer development. When this mutation occurs, the structure of the p53 protein becomes unstable, causing it to lose its original function. LG00313112 works by stabilizing the mutated p53 protein, thereby helping to restore its tumor-suppressing function.


LG Chem explained that it applied a first-in-class covalent drug design within this category, which enhances binding strength to the target and is expected to provide sustained therapeutic effects. In preclinical studies, antitumor efficacy and durability of response were observed even at low doses, and antitumor activity was maintained in tumor models harboring both TP53 and KRAS mutations.


According to The Cancer Genome Atlas (TCGA) data from the U.S. National Cancer Institute (NCI), the average post-treatment survival period for cancer patients with TP53 mutations is 29 months, which is shorter than the 63 months observed in patients without the mutation. Currently, there are no approved therapies that directly target the TP53 Y220C mutation.


To accelerate development, LG Chem has adopted a phase 1/2 clinical design that combines both phases under a single protocol. The strategy is to confirm the appropriate dose and efficacy in the early stage, thereby shortening the overall development period.


In phase 1, the trial will evaluate safety, tolerability, recommended phase 2 dose, and initial efficacy in patients with advanced solid tumors such as ovarian, lung, and breast cancers that carry the TP53 Y220C mutation. Based on phase 1 results, phase 2 will focus on a more comprehensive validation of efficacy.



Hyejin Kim, Head of Clinical Development at LG Chem, stated, "Through a biomarker-based precision medicine approach, we will identify patients who are likely to respond to treatment and increase the chances of successful new drug development. We will accelerate the development of LG00313112 for cancer patients with limited treatment options."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing